Agilent Technologies, Inc.
AHealthcareNASDAQDiagnostics & Research · Last scanned Jul 18, 2026
Scan Results
Daily timeframeAgilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. With a market capitalization of $37.13B, it sits in large-cap territory. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
Market Cap
$37.13B
Beta
1.25
P/E (TTM)
27.33
P/E (Fwd)
19.88
EPS (TTM)
$4.81
EPS (Fwd)
$6.61
ROE
21.3%
ROA
8.6%
Cash
$1.81B
Total Debt
$3.54B
Free CF
$930.6M
52W Change
15.3%
Annual Financials
Cash vs Debt
Agilent Technologies, Inc. carries $3.54B in total debt against $1.81B in cash reserves — debt is roughly 2.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $930.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 21.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $6.85B (2022) to $6.95B (2025).
Investors considering Agilent Technologies, Inc. should weigh the typical risks associated with A's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing A.